At Year One Labs, one of the litmus tests for us as advisors and investors was the clarity with which a team understood, and tracked, their OMTM. If it was on the tip of their tongues, and aligned with their current stage, that was a good thing. If they didn’t know what it was, if it was the wrong metric for their stage, if they had several metrics, or if they didn’t know what the current value was, we knew something was wrong.
